



COMMUNICATION AND PUBLIC EDUCATION COMMITTEE

Nicole Thibeau, PharmD, Licensee Member, Chairperson
Jason Newell, Public Member, Vice Chairperson
Renee Barker, PharmD, Licensee Member
Claudia Mercado, Public Member
Ricardo Sanchez, Public Member

I. Call to Order and Establishment of Quorum

II. Public Comment for Items Not on the Agenda; Matters for Future Meetings

The committee may not discuss or act on any matter raised during the public comment section that is not included on this agenda, except to place the matter on a future meeting agenda. [Government Code sections 11125 & 11125.7(a)]

III. Approval of the July 18, 2024, Communication and Public Education Committee Meeting Minutes

A draft of the minutes is in **Attachment 1**.

IV. Education Materials on Buprenorphine

Background

On February 6, 2025, the Board received a presentation on the challenges patients face when trying to receive addiction medication such as buprenorphine. Patients who display red flag behaviors at pharmacies can be denied access to their medication. Several doctors and healthcare advocates provided explanations for certain patient behaviors, such as why multiple patients may have the same address, why a patient appears nervous and anxious, or the reason a patient may try to obtain an early refill of their medications.

At Today's Meeting

The Board would like to educate pharmacists on how to handle these cases. Staff have developed educational materials, which are included in **Attachment 2**.

V. Discussion and Consideration of Committee's Strategic Objectives 2022-2026

Background

Communication and Public Education Committee Meeting – June 12, 2025

The Board's [Strategic Plan 2022-2026](#) includes eight goals that guide policies and actions implemented by the Communication and Public Education Committee.

For Committee Consideration and Discussion

During the meeting, members will have the opportunity to review the strategic objectives and the actions taken to achieve them. Staff requests that the committee consider whether the current objectives remain suitable or whether specific objectives should be revised or new objectives considered. Staff has listed the goals in this report and provided comments for each goal for the committee's consideration. After reviewing the goals, committee members are welcome to give comments or direction to staff regarding the strategic objectives.

4.1 Develop a consumer education campaign to educate consumers about the Board and the importance of pharmacy services, including patient consultation.

July 2022 Status: The Board undertakes a rulemaking to update the Board's Notice to Consumers poster and regulation, [CCR section 1707.6](#), to provide consumers with more relevant information about their rights and an explicit reminder to consult their pharmacist about their medications.

July 2023 Status: Staff propose revisions to the Notice to Consumers poster and elements of the consumer education campaign.

July 2024 Status: Staff completes [Notice of Consumer poster](#) and mails it out to all pharmacies in California. In addition to the NTC poster, titled "Talk to an Expert," a "Point to Your Language" poster was included in the mailing. There are 16 languages on the Point to Your Language posters, 4 of which are new to the list. They include Japanese, Hindi, Thai, and Punjabi. A public education campaign was created to bring awareness to the revised NTC poster.

July 2025 Status: Staff produced a campaign to direct consumers to the Board's website to view educational materials on opioid safety, online pharmacies, and contraception as part of National Drug and Alcohol Facts Week 2025. Additionally, Staff created an education campaign to remind patients that pharmacists are healthcare providers and can assist with medication review to prevent medication errors as part of National Medication Safety Week 2025.

4.2 Reevaluate, and update, if necessary, educational materials related to pharmacy law to assist licensees in operating in compliance.

July 2022 Status: The Board continuously updates key resources to keep licensees informed on pharmacy law and regulations. The online [Pharmacy Lawbook](#) is updated regularly with newly adopted laws and regulations. The Board also creates a new [pharmacy law webinar](#) each year. In addition, the Board posts constant updates to [pharmacy law waivers](#) online and proactively disseminates updates about laws, regulations, and waivers in subscriber alerts and The Script.

July 2023 Status: Frequently Asked Questions are developed related to the use of [mobile units](#). Further FAQs are revised to ensure information remains current, including the [continuing education FAQ](#) and [ADDS FAQs](#). Various [self-assessment forms](#) are updated to reflect changes in pharmacy law and the new 2023 [pharmacy law webinar](#) is available.

July 2024 Status:

Frequently Asked Questions developed for [Assembly Bill 1286](#). Developed notice regarding exemptions with [Tribal Health Care Providers](#). Updated [Pharmacy Law Webinar](#) for 2024.

Revised educational materials to ensure information is current for the following:

- [Continuing Education](#),
- FAQs for the [Revision to Inventory Reconciliation](#),
- [Mobile Units](#),
- [Pharmaceutical and Sharps Waste Stewardship Programs](#),
- [Compounding Policy Statement](#),
- [Notice to Licensees Regarding CURES version update](#),
- [Digital Signature policy](#).

July 2025 Status: The Board developed educational materials related to Compounded Drug Preparations, specifically a Summary of Changes to the Board of Pharmacy's Proposed Regulations about Compounding, [Temporary Provisions for Compounding Certain Parenteral Drug Products](#), [Compounding FAQs](#), and [Compounding Presentations by Board Counsel and Board Executive Officer](#).

Additionally, the Board updated the [Notice to Licensees Regarding CURES Version Update and the](#) FAQs for [Assembly Bill 1286](#).

4.3 Promote the self-assessment process to educate licensees about the importance of the tool.

July 2022 Status: Staff is currently working with DCA's Office of Information Services to evaluate the feasibility of transforming the self-assessment forms to an online, more interactive process that would actively engage pharmacists in ensuring their operations comply with pharmacy law.

July 2023 Status: Staff complete business process mapping with the DCA's Organizational Improvement Office.

July 2024 Status: Staff completed and implemented the Surgical Clinic Self-Assessment developed under AB 1286. The Board approved self-assessments for the Automatic Drug Delivery System (ADDS), the Community Pharmacy/Hospital Outpatient, and the Whole Seller; the Board is currently pursuing role making action to implement.

July 2025 Status: Staff completed and Posted Updated Forms to the Board's website for the following:

- Revised [Automated Drug Delivery System Self-Assessment](#)
- [Draft Community Pharmacy Self-Assessment/Hospital Outpatient Pharmacy Self-Assessment](#)
- [Draft Hospital Pharmacy Self-Assessment](#)
- [Wholesaler/Third-Party Logistics Provider Self-Assessment](#)

4.4 Create an educational program for the colleges of pharmacy and a required training prior to obtaining an intern license to ensure an understanding of the Board and its consumer protection mandate.

July 2022 Status: Board staff provide outreach at pharmacy schools by providing presentations to pharmacy students on licensing requirements and how to complete applications for both pharmacist and intern pharmacist licenses.

July 2023 Status: Board staff provide outreach at pharmacy schools by providing presentations to pharmacy students on licensing requirements and how to complete applications for both pharmacist and intern pharmacist licenses.

July 2024 Status: President Oh and Board staff provided presentations to students at several pharmacy schools in California. This was part of pharmacy law curriculum.

July 2025 Status: Board staff provide outreach at pharmacy schools by providing presentations to pharmacy students on licensing requirements and how to complete applications for both pharmacist and intern pharmacist licenses.

4.5 Increase outreach and education to licensees to expand knowledge of the Board and to promote compliance.

July 2022 Status: Staff continue to provide continuing education to pharmacists on preventing drug abuse and drug diversion. The online platform has enabled staff to provide the training to more pharmacists statewide than live events permitted before the pandemic. As conditions improve, staff hopes to offer more outreach events in person as well as via WebEx. In addition, licensing staff has started providing presentations at California schools of pharmacy on how to apply for an intern pharmacist license and how to apply to take the pharmacist exam. Staff provides in-person and live WebEx presentations on Board activities and changes in pharmacy law.

July 2023 Status: Staff continue to provide continuing education to pharmacists on preventing drug abuse and drug diversion. The online platform continues to enable staff to provide the training to a larger audience statewide than live events permitted before the pandemic. Staff provides in-person and live WebEx presentations on Board activities and changes in pharmacy law.

July 2024 Status: Staff continue to provide continuing education to pharmacists on preventing drug abuse and drug diversion. The online platform continues to enable staff to provide the training to a larger audience statewide than live events permitted before the pandemic. Staff provides in-person and live WebEx presentations on Board activities and changes in pharmacy law. Staff provide a presentation at patient safety conference.

July 2025 Status: Staff continue to provide continuing education to pharmacists on preventing drug abuse and drug diversion. The online platform continues to enable staff to provide the training to a larger audience statewide than live events permitted before the pandemic. Staff provides in-person and live WebEx presentations on Board activities and changes in pharmacy law.

Staff reached out to licensees during the January 2025 fires in Southern California to provide guidance on compliance during a state of emergency:

- [Waiver Related to Delivery Provisions](#)
- [Waiver of Staffing Ratio Provisions](#)
- [Waiver Related to Remote Processing](#)

4.6 Create more webinars to post on the website to disseminate basic information.

July 2022 Status: The Board recently posted a training webinar for pharmacists furnishing HIV PrEP/PEP medications pursuant to SB 159. To gauge participants' comprehension of the training material, the webinar includes a 10-question assessment that participants must pass in order to receive a certificate of completion. The training program is the latest in a series of educational webinars of important topics – including law, ethics, furnishing naloxone, and preparing for an inspection – that the Board has developed and made available for free to inform and educate licensees.

July 2025 Status: The Board expanded its continuing education training by adding a new Pharmacist-in-Charge training webinar. In addition to this new webinar, the Board has a new Learning Management System designed to make CE training more user-friendly for licensees. The Board also released its updated pharmacy law and Naloxone training.

4.7 Improve communication to licensees by personalizing it and decreasing verbiage to encourage licensee engagement.

July 2022 Status: The Board has established listservs for each type of personal license to better target subscriber alerts to pharmacists, pharmacy technicians, designated representatives, and intern pharmacists. In addition, staff keep communications in subscriber alerts and Script article as succinct and direct as possible.

July 2023 Status: The Board continues to use the dedicated listservs to target information to appropriate audiences.

July 2024 Status: The Board continues to use listservs and The Script newsletter to communicate with licensees. Social media X is also used to encourage licensee engagement.

July 2025 Status: The Board continues to use listservs and The Script newsletter to communicate with licensees. Social media X is also being used more frequently to encourage licensee engagement.

4.8 Research creating a recognition program for pharmacists to help build relationships between public, licensees, and the Board.

July 2022 Status: The Board honors pharmacists who have maintained their California pharmacy license on active status for 40 years or more. These pharmacists are identified publicly in The Script and [online](#) and invited to be recognized and honored at Board meetings.

July 2023 Status: The Board continues to honor pharmacists who have maintained their California pharmacy license on active status for 40 years or

more. These pharmacists are identified publicly in The Script and [online](#) and invited to be recognized and honored at Board meetings.

July 2024 Status: The Board continues to honor pharmacists who have maintained their active licenses for 40 years or more. These pharmacists are publicly identified in The Script and online and are invited to be recognized and honored at Board meetings.

July 2025 Status: The Board honors pharmacists who have maintained an active California pharmacy license for 40 years or more. These pharmacists are identified publicly in The Script and [online](#) and invited to be recognized and honored at Board meetings. The Board recognized pharmacists during National Pharmacy Week.

VI. Update on Communication and Public Education Activities by Staff

a. The Script

The Board has recently released its May 2025 newsletter.

b. Staff Outreach

1. Presentation and Training A list of activities by individual staff members is in **Attachment 3**.

c. News Media Inquires

1. A list of media is in **Attachment 4**.

VII. Future Meeting Dates

The dates for future committee meetings can be found on the website.

VIII. Adjournment

Upon Conclusion of Business

Attachment 1



Communication and Public Education Committee DRAFT Meeting Minutes

DATE: Thursday, July 18, 2024

LOCATION: California State Board of Pharmacy
2720 Gateway Oaks Drive, Hearing Room, First Floor
Sacramento, CA 95833
Participation also through teleconference via Webex

COMMITTEE

MEMBERS PRESENT: Jason Weisz, Public Member, Chairperson
Nicole Thibeau, PharmD, Licensee Member, Vice
Chairperson
Renee Barker, PharmD, Licensee Member
J. Newell, Public Member
Kartikeya (K.K) Jha, Licensee Member

STAFF PRESENT: Anne Sodergren, Executive Officer
Debbie Damoth, Executive Specialist Manager
Sara Jurens, Public Information Officer
Shelley Ganaway, Board Counsel

I. Call to Order and Establishment of Quorum

Chairperson Weisz called the Communication and Public Education Committee meeting to order at 2:00pm. Mr. Weisz reminded all present that the Board is a consumer protection agency. Mr. Weisz advised the meeting was being conducted in person and through teleconference via Webex. Mr. Weisz asked the moderator to provide general instructions on providing public comment via Webex. The meeting moderator provided updated WebEx instructions for members of the public participating in the meeting. Mr. Weisz took roll call: Present: Renee Barker, J. Newell, Nicole Thibeau, Kartikeya (K.K.) Jha and Jason Weisz. Quorum established.

II. Public Comment for Items Not on the Agenda; Matters for Future Meetings

Members of the public were provided the opportunity to provide comments for items not on the agenda; however, no comment was provided.

III. Approval of the January 22, 2024, Communication and Public Education Committee Meeting Minutes

Chairperson Weisz referenced the draft minutes from the January 22, 2024, Communication and Public Education Committee meeting.

Members were provided an opportunity to comment.
No comments were made.

Motion: Approve the January 22, 2024, Communication and Public Education Committee meeting minutes as presented in the meeting materials.

M/S: Thibeau /Barker

Members of the public were provided with an opportunity to provide public comment; however, no comment was provided.

Support: 5 Oppose: 0 Abstain: 0 Not Present: 0

Committee Member	Vote
Barker	Support
Thibeau	Support
Jha	Support
Newell	Support
Weisz	Support

IV. Transition to a New Website Template

Members received an update on the transition to the new website template. Staff has completed the conversion of the website to a newer template. At the time of the committee meeting, the website was under review with DCA's internet team.

Following the meeting, the conversion to the new website was completed. A subscriber alert was released announcing the new website template.

V. Talk to the Expert Consumer Poster and Public Education Campaign

Members received an update on the Talk to the Expert campaign. Members were informed that approximately 6,000 posters have been mailed out to all pharmacies in California. In addition to the Talk to the Expert poster, a Point to Your Language poster was included in the mailing. The Point to Your Language posters include 16 translations and the posters were updated to include four new languages. The four new languages added were Japanese, Hindi, Thai, and Punjabi.

Members were reminded of the public education campaign that was created to bring awareness to the revised NTC poster. The campaign was distributed the week of July 8th to the Department of Consumer Affairs (DCA), the Board's social media account (formally Twitter), on the Board's subscriber alert and on the Board website. The campaign will run again in August as a follow up reminder to licensees. Members requested that staff maintain the education campaign for use in the future as a reminder beyond August as an important resource for patients.

Further, as part of the discussion, members requested that staff evaluate for opportunities to partner with the Enforcement and Compounding Committee on efforts to address barriers to patient consultation.

VI. Committee's Strategic Objectives

The Committee's Strategic Objectives were made available for members to review. Staff listed the objectives in this report and provided comments for each objective for the committee's consideration. After reviewing the objectives, committee members were offered the opportunity to provide comments or direction to staff regarding the strategic goals.

VII. Draft Educational Material Related to IV Hydration Clinics

During the meeting members reviewed draft educational materials intended to be provided to personnel at IV hydration clinics as well as made available on the Board's website. The focus of the education is around legal requirements and patient safety considerations for such clinics.

During the meeting members generally spoke in support of the concept of the education and requested that staff work to refine the materials. Members requested that staff work with Member Barker to incorporate edits requested by the committee and to provide an updated version for the Board's consideration.

Following the meeting staff had an opportunity to work with Member Barker. Some of the significant changes made to the document include:

1. Reorganization of information and simplifying language to more explicitly state the potential harm to patients.
2. More directly referenced the relevant sections of USP 797 – Pharmacy Compounding – Sterile Preparations

Consistent with the request from the committee, staff will also be exploring the ability to create an educational video.

Board staff will continue to engage with other healing arts boards on the materials and will continue to offer co-branding of the document with programs that are interested.

VIII. Communication and Public Education Activities by Staff

The Board's Public Information Officer, Sara Jurrens, gave a report on activities by staff.

The Script

The Board released two newsletters since the previous Committee meeting. In [March 2024](#), a special edition of The Script was released that focused on AB 1286, the patient safety measure. This edition included a summary of changes, the implantation statement, an explanation on how the Board will hire a third party for collecting and reporting medication errors, and frequent asked questions (FAQ's).

In [May 2024](#), an issue of The Script was released, and a few of things that were published included how San Diego is expanding access to care with their pharmacy mobile unit, protected reproductive and gender affirming health care services, a reminder for pharmacist about Medicare prescription costs, the statewide standing order in schools on epinephrine, name and gender request changes, and more.

Staff Outreach

Presentation and Training: A list of activities by individual staff members, from January to June, was made available for Committee members.

Fake Botox

Committee members were informed of the messaging shared on social media from the California Department of Public Health (CDPH) on the serious health risks related to counterfeit versions of Botox. Pictures were included to show what to look for in packaging.

News Media Inquires

Committee members were informed of the news media inquiries, including interest in disciplinary reports for a pharmacy in Texas, interest in GLP-1 medications, a question regarding a CVS closing.

Members of the public were provided with an opportunity to provide public comment. No comments were made in person in Sacramento or via Webex.

IX. Future Meeting Dates

Chairperson Weisz thanked everyone for their time and noted that the proposed date for the next meeting will be January 9, 2025.

X. Adjournment

The meeting was adjourned at 2:38pm.

Attachment 2

Corresponding Responsibility Considerations for Dispensing Buprenorphine

State and Federal law make clear that pharmacists share a corresponding responsibility with prescribers to ensure that controlled substances are dispensed for a legitimate medical purpose and in the usual course of professional practice.

When fulfilling this legal obligation, pharmacists evaluate the four corners of the prescription to verify the legitimacy of the prescriber and the appropriateness of prescription. Buprenorphine is primarily used in the treatment of Opioid Use Disorder (OUD) and as such, the clinical purpose of the prescription must be considered as part of a pharmacist's assessment. While many other opiates pose a high risk of abuse potential for patients, buprenorphine when used to treat OUD, is used to prevent withdrawal, to reduce cravings, and support recovery. Given the clinically significant difference in the use for buprenorphine, it is important for pharmacists to be mindful that red flags typically assessed may not be appropriate for patients receiving prescriptions for buprenorphine. As an example, the distance between the pharmacy and or the prescriber and the patient may not be a red flag if the patient is receiving buprenorphine via telehealth.

Additional resources are available to assist pharmacists in identifying practice considerations, including ["The Pharmacy Access to Resources and Medication for Opioid Use Disorder \(PhARM-OUD\) Guideline, A Joint Consensus Practice Guideline from the National Association of Boards of Pharmacy and the National Community Pharmacists Association."](#)

Attachment 3

Board of Pharmacy (BOP)

Attachment #3 – Staff Outreach Activities

Board staff reported the following outreach activities:

- Presentation on misbranded drugs for the California Veterinary Medical Board on January 28, 2025.
- Presentation on Pharmacy Law Updates for the California Pharmacists Association, October 2024 and April 2025
- Presentation on Board of Pharmacy for the California Society of Health Systems Pharmacists October 2024
- Presentation on Legislative Updates for the California Society of Health Systems Pharmacist April 2024
- Participation on State Regulatory Panel, FDA Intergovernmental Working Meeting on Drug Compounding June 2025
- Presentation on the Board of Pharmacy, Tour University January 2025
- Presentations on the application and examination process were given to pharmacy schools on:

March 2025

10 - Western University of Health Sciences

11 - Chapman University

13 - University of California, San Diego

28 - California Northstate University

28 - Loma Linda University

31 - University of the Pacific

April 2025

1 - Keck Graduate Institute

10 - University of California, San Francisco

May 2025

5 - American University of Health Sciences

Attachment 4

Attachment #4 – News Media Inquiries

July 1, 2024 – June 1, 2025

2024

7/17, Austin Murphy, Santa Rosa Press Democrat, requested information on the Board's position of compounded glutathione. On 7/21, Murphey contacted a Board member via private email, requesting an interview. On 7/23, the reporter contacted a second Board member via private email, requesting an interview.

7/25, Emily Baumgaertner, New York Times, requested information on the impact of heat exposure on mail order medications.

7/29 Rachel Bluth, Politico, requested information on compounding. The reporter was looking to understand regulations. The reporter said she heard criticism that proposed regulations would prevent pharmacies from compounding Category 1 drugs that hadn't made it fully to the FDA bulk list.

7/31, Matt Mitchell, Point Reyes Light, requested violation information on the West Marine Pharmacy and its owner.

8/2, Marla Tellez, Fox 11, Los Angeles, asked why the Board is proposing new regulations that would ban Category 1 sterile compounds, why did the Board decide to delay a decision until September, the effects of "Stop the BOP" petition, and how does the BOP respond to firefighters who believe that glutathione reverses heavy metal toxicity.

8/20, Brittany Trang, STAT News, requested the number of complaints BOP received when mail-order CarelonRX mailed out incorrect prescriptions at the beginning of 2024. The reporter requested complaints for Elevance, Anthem, Carelon and CarelonRX. On 8/30, the reporter followed up asking for a breakdown of the complaints.

8/29, Volunteer Laurie, Call Kurtis CBS 13, contacted the BOP on behalf of a viewer who claims she is having trouble receiving her license due to issues with her identification and passport.

9/6, Deanna Robertson, KCRA, requested the number of pharmacists certified to prescribe birth control, the number of retailers/pharmacies where women can request a birth control prescription from a pharmacist, the number and type of prescriptions written by a pharmacist, since 2019.

9/13, Patricia Callahan, ProPublica, contacted BOP regarding laws and regulations on a drug recall BOP posted on 6/24/2024 for manufacturer Glenmark. The reporter wants to know who contacted BOP and when. The reporter is interested in knowing about policies, recall alerts and how quickly BOP makes recall alerts.

9/18, Austin Murphy, *Santa Rosa Press Democrat*, contacted the BOP to ask what regulations or laws pharmacies are violating with compounding glutathione and methylcobalamin, drugs that firefighters claim can detoxify those exposed to smoke, and what is BOP's response to allegations that BOP is enforcing underground regulations. In addition, the reporter wants to know cases where Administrative Law Judges concurred with BOP.

9/27, Austin Murphy, *Santa Rosa Press Democrat*, submitted a Public Record Act to the BOP for emails and text messages of several staff and board members from January 2019 to September 2024 in connection with compounding meetings.

10/3, Beki San Martin, *San Francisco Standard*, requested information on the challenges impacting pharmacists that create long wait times for consumers, specifically naming Walgreens on Polk Street in San Francisco. Reporter is requesting to speak with a representative with the California Pharmacists Association and Walgreen in SF. On 10/16, the reporter asked to speak with someone at BOP for comment.

10/4, Gerri Constant, KCAL, contacted the BOP asking the Board's position on GLP-1 medications, semaglutide and terzepetide.

10/7, Charles Russell Havens, *San Deigo Cannabis Times*, contacted BOP asking how many licensed pharmacies are in San Diego County.

10/16, Irena Hwang, ProPublica, contacted the BOP to ask how BOP notifies pharmacies and consumers about recalls and how recalls are shared through the subscriber emails.

10/23, Brian Nowosielski, Drug Topics, requested an interview with a Board member to discuss the impacts communities experience that lack access to pharmacies.

10/29, Richard Wieland, *Freedom Magazine*, requested information on Reinhold Mueller Jr., ([#RPH 39765](#)) for a story about successful pharmacists.

10/31, Dave Manoucheri, KCRA, requested information on compounding regulations and what lead to the proposed change in regulations.

11/4, Sneha SK, Reuters, and Lauren Gardner, Politico, contacted the BOP to request a contact email and phone number for Fullerton Wellness in Ontario following an [FDA alert](#) warning providers not to use compounded GLP-1s, a weight management drug, made at this facility.

11/21, Kasturi Pananjady, *Associated Press*, contacted the BOP for confirmation that the licensee list downloads provided on the [DCA data portal](#) include physical addresses for pharmacies.

11/25, Sydney Lupkin, NPR, contacted the BOP to fact check a story that previously ran on NPR on the investigation of Fullerton Wellness. The reporter also asked if it was accurate that Fullerton is a wellness business and not a pharmacy.

11/27, Ben Lee, *Chemist + Druggist*, contacted the BOP to get clarification on a press release about the sentencing of a Madera pharmacist.

2025

1/9, Lauren Biscaldi, *Drug Topic*, requested information on medication access for wildfire evacuees.

1/14, Ike Swetlitz, Bloomberg, asked if BOP has issued discipline to pharmacies related to compounded GLP-1 drugs commonly used for weight loss, and if

there are any ongoing investigations related to the drugs.

1/27, Lauren Lantry, Nightline, requested an interview on counterfeit Ozempic and other GLP-1 drugs for an episode of "Impact x Nightline" on Hulu.

1/27, Emma Croteau, Arizona State University Investigative Journalism Program, requested data on violations, inspections and complaints of compounding pharmacies in California from January 1, 2020, to the present.

2/18, Jarret Liotta, *Los Angeles Daily News*, requested information on the compounding of glutathione in IV hydration treatments. Firefighters claim the drug can detoxify those exposed to smoke.

2/28, Alaa Mostafa, KALW Public Media, requested information on operating dates of two Oakland pharmacies.

3/4, Carolyn Johnson, NBC Los Angeles, requested an interview regarding BOP's position on glutathione.

3/4, Julian Gill, *Houston Chronicle*, requested copies of all adverse event reports and complaints associated with Empower Pharmacy.

3/24, Ed Silverman, *The Boston Globe*, requested information on accusations against Amazon's PillPack.

3/24, Shelby Livingston, *Endpoint News*, requested information on a license application denial for Empower Pharmacy in Houston.

3/27, Austin Murphy, *Santa Rosa Press Democrat*, contacted BOP for a follow up article on regulations that were passed for compounding glutathione.

4/1, Julian Gill, *Houston Chronicle*, requested email correspondence between BOP and Empower Pharmacy's CEO Shaun Noorian in June 2020.

4/9, Shellye Leggett, Spectrum News, requested an interview on Trump's announcement regarding pharmaceutical tariffs.

4/22, Julian Gill, *Houston Chronicle*, requested information on a 2019 subscriber alert sent by BOP that informed pharmacies of improper sterile compounding practices with dietary supplement grade ingredients and asked if the alert was connected to the investigation into Empower.

5/12, Megan Cassidy, *San Francisco Chronicle*, asked if hospitals are required to report drug losses.

5/28, Ike Swetlitz, Bloomberg, looking for information on citations issued to pharmacies for vaccine quotas.